Abstract 363P
Background
The treatment of PD-L1-positive mNSCLC patients with immune checkpoint inhibitors (ICI) has led to a significant improvement in survival rates. However, a large proportion of patients with mNSCLC do not respond to ICI. The determination of PD-L1 expression as a predictive biomarker can indicate which pts are likely to benefit from ICI. However, PD-L1 expression alone does not always correlate with response. Additional biomarkers of response and resistance to ICI are needed to optimize treatment selection for pts with mNSCLC. Therefore, the effects of the following mutations KRAS, STK11, KEAP1, TP53, ARID1A and POLE on PFS and OS in pts with mNSCLC will be investigated.
Methods
In retrospective study a total of 212 PD-L1 positive mNSCLC pts were analyzed for the following mutations: KRAS, STK11, KEAP1, TP53, ARID1A and POLE. The pts were first diagnosed between 2018 and 2023 in a cancer center in northern Germany. Clinical data including sex, age, smoking status, as well as PD-L1 score was captured. Detailed information on the course of treatment and the survival will be presented at the conference.
Results
Median age of the 212 pts was 65 years (36–88 yrs) and 54% (115/212) of them were male. Most of the pts had an ECOG 0/1 (%; 174/212) and 90% of them were current/ex heavy smoker (n=192/212). PD-L1 groups are distributed as follows: 23,6% (50/212) pts with a PDL1
Conclusions
OS and PFS are calculated from the start of ICI or ICI in combination with chemotherapy and correlated with the various biomarkers. In addition, an adjusted Cox regression will be performed at the conference to assess the predictive value of the various biomarkers.
Funding
Has not received any funding
Disclosure
J. Roeper: Financial Interests, Personal, Invited Speaker: Astra, BI, Roche. F. Griesinger: Financial Interests, Personal, Invited Speaker: ASTRA, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Siemens; Financial Interests, Personal, Writing Engagements: ASTRA, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Ariad, AbbVie, Siemens; Financial Interests, Personal, Speaker’s Bureau: Astra, Boehringer, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Ariad, AbbVie, Siemens; Financial Interests, Personal, Advisory Board: Astra, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Siemens; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Siemens. All other authors have declared no conflicts of interest.